Ripple Science has announced new initiatives to help clinical researchers continue their work through COVID-19. Many clinical trial teams are working remotely and have paused patient visits, forcing teams to do more of their work online. Ripple Science wants to help researchers continue their research during this uncertain time by giving research teams free access to Ripple for their first study. For those working on COVID-19 trials directly, the company is providing six-months of access to Ripple free of charge.
Ripple is a web-based platform designed for clinical research teams who want a secure and streamlined way to recruit, manage, and retain patients for trials. Ripple is a purpose-built CRM and project manager which organizes clinical trial recruiting and research efforts. Debi Gross, Community Outreach Director for Stony Brook University’s autism initiative, stated, “The fact that Ripple is web-based is a game-changer for us...The time between when participants contact us to enrolling them in a study seems a lot shorter and quicker.”
Peter Falzon, President and CEO of Ripple Science, commented, "We are committed to supporting research teams to work remotely and communicate with patients differently in response to COVID-19. Our customers have been telling us what they need and how Ripple helps, and we are responding to their needs by accelerating feature updates and expanding access.”
In the upcoming weeks, Ripple Science will release features aligned to even better support the initiatives of researchers working in this new paradigm.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.